PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
51 hedge funds and large institutions have $73.4M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 20 closing their positions.
99% more call options, than puts
Call options by funds: $275K | Put options by funds: $138K
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
16% less funds holding
Funds holding: 61 → 51 (-10)
23% less capital invested
Capital invested by funds: $95.8M → $73.4M (-$22.4M)
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$2.23M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
+$1.19M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$945K |
| 4 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
+$767K |
| 5 |
BlackRock
New York
|
+$502K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.49M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$3.36M |
| 3 |
ACM
Altium Capital Management
New York
|
-$2.41M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.33M |
| 5 |
EP
Eversept Partners
New York
|
-$933K |
PHAS Hedge Fund Activity: Q4 2021 in Review
51 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q4 2021, worth a combined $73.4M — down 23% from $95.8M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of PHAS and 10 opened new positions — a net loss of 10 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $2.23M. The largest seller was Wellington Management Group, cutting an estimated $3.49M.
- 51 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q4 2021, down from 61 in Q3 2021.
- Funds reported $73.4M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q4 2021, down 23% quarter-over-quarter.
- 10 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q4 2021 and 20 closed out, a net change of -10 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Rock Springs Capital Management, an estimated $2.23M added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q4 2021 was Wellington Management Group, an estimated $3.49M sold.
Based on aggregated 13F filings for Q4 2021.